Skip to content

A prospective, randomized, multicenter clinical trial evaluating the safety and efficacy of a short-term anticoagulation strategy after pulsed field ablation in patients with atrial fibrillation at low risk of stroke (SAFE-PFA trial)

A prospective, randomized, multicenter clinical trial evaluating the safety and efficacy of a short-term anticoagulation strategy after pulsed field ablation in patients with atrial fibrillation at low risk of stroke (SAFE-PFA trial)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0011362
Enrollment
200
Registered
2025-12-19
Start date
2025-12-30
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others(left bundle branch area pacing, LBBAP + AVJ ablation) : 1. All study participants will undergo pulmonary vein isolation (PVI) according to a standardized protocol using the Varipulse™ system. 2

Sponsors

Yonsei University Health System, Severance Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adults aged 19 years and older with paroxysmal atrial fibrillation (AF). 2. Patients scheduled for their first pulmonary vein isolation (PVI) using the Varipulse™ pulsed-field ablation system. 3. Stroke low-risk patients with a CHA2DS2-VA score of 0 or 1. 4. Patients who have been on anticoagulation therapy for at least 3 weeks prior to the procedure. 5. Patients who fully understand the study objectives, procedure, and anticoagulation strategies, and have provided written informed consent.

Exclusion criteria

Exclusion criteria: 1. Persistent or long-standing persistent atrial fibrillation. 2. CHA2DS2-VA score = 2. 3. History of prior left atrial ablation, pulmonary vein isolation, or other heart surgery. 4. Contraindication to anticoagulant use or patients at high risk of severe bleeding. 5. History of ischemic stroke, transient ischemic attack (TIA), or systemic embolism within the past 30 days. 6. Active bleeding or uncontrolled bleeding disorders. 7. Malignant tumors, severe liver disease, renal failure, or patients with an expected survival of less than one year. 8. Pregnant or breastfeeding women. 9. Patients for whom follow-up in accordance with the study protocol is deemed difficult. 10. Other patients deemed unsuitable for participation in the clinical trial at the discretion of the investigator.

Design outcomes

Primary

MeasureTime frame
The incidence rate of composite events occurring within 3 months after the procedure

Secondary

MeasureTime frame
Comparison of the incidence rates of individual events such as thromboembolism and bleeding;Comparison of adherence to anticoagulant therapy.;Cost-effectiveness analysis;Comparison of patient-reported outcomes (PROs);Incidence rate of major cardiovascular events.

Countries

Korea, Republic of

Contacts

Public ContactAnna Choi

Yonsei University Health System, Severance Hospital

cardiocrc58@yuhs.ac+82-2-2228-8522

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026